Aligos is developing a capsid assembly modulator, ALG-000184, as a hepatitis B treatment. The South San Francisco, California-headquartered company presented data for the therapy at the June 2024 European Association of Liver Disease (EASL) Congress in Italy.

As WHO reports a high HBV burden, Aligos Therapeutics’ CEO highlighted the potential for pharma to address unmet needs.

As the inventor of the Araris ADC Technology, Philipp has a profound background in Bioconjugation and ADCs. He was the founding CEO since the inception of Araris in 2019 securing $40M in financing from Swiss, UK, US and Korean investors and $2.5M non-dilutive financing from the Swiss Accelerator Grant (5% funding rate).

Discover how Cue Biopharma harnesses the curative potential of the body’s intrinsic immune system to develop treatments for oncology and autoimmune diseases. Here, Anish Suri, Chief Scientific Officer of Cue Biopharma, explains how its platforms and biologics are designed to selectively modulate disease-specific T cells to restore immune balance, aiming to improve efficacy and minimise adverse effects.

The traditional approach to treating autoimmune disease has relied on ways to suppress the immune system. COUR Pharmaceuticals is developing first-in-class therapies that instead seek to reprogram the immune system to create antigen-specific tolerance. We spoke to COUR CEO John Puisis and COUR Vice President of Research Adam Elhofy, about how the company’s immune-modifying nanoparticles work, how the approach preserves the immune response, and its partnership with Takeda focused on celiac disease.

Zandy Forbes, Founder, President, and CEO of MeiraGTx, joins host Rahul Chaturvedi in this compelling episode. Zandy shares her inspiring journey from academia, where she developed a deep interest in molecular biology and genetics, to her significant role in biotech investing, and eventually leading a groundbreaking gene therapy company

In this post-ASCO interview with CUE Biopharma chief medical officer Matteo Levisetti, Levisetti tells pharmaphorum editor-in-chief Jonah Comstock about how his company’s tumour-specific T-cell engagers could create new opportunities for cancer immunotherapies to succeed.

“It’s an encouraging and exciting time to be in psychiatry because we now have tools available, even in clinic, that show a rapid and robust clinical response, and there are more to come,”